Viral Protease Inhibitors

Compounds that specifically inhibit PROTEOLYTIC ENZYMES that are encoded by VIRUSES.

Also Known As:

Inhibitors, Viral Protease; Inhibitors, Virus Protease; Protease Inhibitor, Viral; Protease Inhibitors, Viral; Protease Inhibitors, Virus; Viral Protease Inhibitor; Inhibitor of Viral Protease; Virus Protease Inhibitors

Networked: 20 relevant articles (3 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 160
  - Therapeutic Uses: 47080
    - Anti-Infective Agents: 8032
      - Antiviral Agents: 47706
        Viral Protease Inhibitors: 20
        HIV Protease Inhibitors: 497
        HCV NS3-4A Protease Inhibitors: 40
        Coronavirus Protease Inhibitors: 1
  - Molecular Mechanisms of Pharmacological Action: 24
    - Enzyme Inhibitors: 1659
      - Protease Inhibitors: 6291
        Viral Protease Inhibitors: 20
        HIV Protease Inhibitors: 497
        HCV NS3-4A Protease Inhibitors: 40
        Coronavirus Protease Inhibitors: 1

Experts

1.	Cossarizza, A: 2 articles (01/2002 - 11/2001)
2.	Mussini, C: 2 articles (01/2002 - 11/2001)
3.	Burnouf, Thierry: 1 article (02/2020)
4.	Faber, Jean-Claude: 1 article (02/2020)
5.	Goubran, Hadi: 1 article (02/2020)
6.	Radosevic, Mirjana: 1 article (02/2020)
7.	Seghatchian, Jerard: 1 article (02/2020)
8.	Absalan, Abdorrahim: 1 article (01/2020)
9.	Ahmadi, Nayebali: 1 article (01/2020)
10.	Chi, Chia-Yu: 1 article (01/2020)

Related Diseases

1.	Acquired Immunodeficiency Syndrome (AIDS) 03/01/2003 - "The recent development and clinical use of three different types of highly effective anti-HIV-1 drugs, including nucleotide and non-nucleotide reverse transcriptase inhibitors (NRTIs) and non-peptidic viral protease inhibitors (PIs) and their combinations, termed highly active antiretroviral therapy (HAART), have dramatically reduced the infection-related mortality of AIDS patients in developed countries. " 06/01/2004 - "Recent advances in the development of three different types of antiviral drugs, the nucleotide and non-nucleotide analogues acting as reverse transcriptase inhibitors (NRTIs) and the nonpeptidic viral protease inhibitors (PI), and their introduction in the management of patients with AIDS, either alone or in combination, have dramatically improved the clinical course of the disease and prolonged life expectancy in patients with AIDS. " 04/01/2004 - "The recent clinical use of potent HIV-1 drugs, including nucleoside reverse transcriptase inhibitors (NRTIs) and non-peptidic viral protease inhibitors (PIs), and their combinations, termed highly active antiretroviral therapy (HAART), has dramatically reduced the infection-related mortality of AIDS patients, but it is associated with severe metabolic adverse events such as lipodystrophy syndrome, dyslipidaemia, insulin resistance and diabetes mellitus. "
2.	Infections 10/01/2017 - "Genotyping these SNPs may be a helpful priority in the treatment of patients with HCV infection, especially in countries where access to triple or double therapy with a viral protease inhibitor is limited." 01/01/2018 - "Telaprevir, a reversible selective inhibitor of viral protease and a potential blocker of viral replication, is indicated for the treatment of hepatitis C virus genotype 1 infection. " 10/01/1998 - "Quinidine and four viral protease inhibitors currently used to treat human immunodeficiency virus infection were tested as chemical inhibitors in this system. " 04/12/2023 - "The lack of specific treatments against this infection and the success of viral protease inhibitors-based treatments against HIV, Hepatitis C, and SARS-CoV-2, brought the monkeypox virus I7L protease under the spotlight as a potential target for the development of specific and compelling drugs against this emerging disease. " 03/01/2003 - "The recent development and clinical use of three different types of highly effective anti-HIV-1 drugs, including nucleotide and non-nucleotide reverse transcriptase inhibitors (NRTIs) and non-peptidic viral protease inhibitors (PIs) and their combinations, termed highly active antiretroviral therapy (HAART), have dramatically reduced the infection-related mortality of AIDS patients in developed countries. "
3.	Lipodystrophy 01/01/2002 - "Only recently a significant impulse to this type of research has come from the observation that the so called "highly active antiretroviral therapy" (HAART), a combination of potent antiretroviral drugs such as viral protease inhibitors or nucleoside-analogue reverse-transcriptase inhibitors, is capable of damaging these organelles and cause a clinical syndrome called lipodystrophy. " 11/01/2001 - "The "highly active antiretroviral therapy" (HAART) is a combination of potent antiretroviral drugs such as viral protease inhibitors or nucleoside-analogue reverse-transcriptase inhibitors, that has a variety of serious side effects, including lipodystrophy, a pathology characterized by accumulation of visceral fat, breast adiposity, cervical fat-pads, hyperlipidemia, insulin resistance as well as fat wasting in face and limbs. " 04/01/2004 - "The recent clinical use of potent HIV-1 drugs, including nucleoside reverse transcriptase inhibitors (NRTIs) and non-peptidic viral protease inhibitors (PIs), and their combinations, termed highly active antiretroviral therapy (HAART), has dramatically reduced the infection-related mortality of AIDS patients, but it is associated with severe metabolic adverse events such as lipodystrophy syndrome, dyslipidaemia, insulin resistance and diabetes mellitus. "
4.	Insulin Resistance 11/01/2001 - "The "highly active antiretroviral therapy" (HAART) is a combination of potent antiretroviral drugs such as viral protease inhibitors or nucleoside-analogue reverse-transcriptase inhibitors, that has a variety of serious side effects, including lipodystrophy, a pathology characterized by accumulation of visceral fat, breast adiposity, cervical fat-pads, hyperlipidemia, insulin resistance as well as fat wasting in face and limbs. " 04/01/2004 - "The recent clinical use of potent HIV-1 drugs, including nucleoside reverse transcriptase inhibitors (NRTIs) and non-peptidic viral protease inhibitors (PIs), and their combinations, termed highly active antiretroviral therapy (HAART), has dramatically reduced the infection-related mortality of AIDS patients, but it is associated with severe metabolic adverse events such as lipodystrophy syndrome, dyslipidaemia, insulin resistance and diabetes mellitus. "
5.	Disease Progression 06/01/2004 - "Recent advances in the development of three different types of antiviral drugs, the nucleotide and non-nucleotide analogues acting as reverse transcriptase inhibitors (NRTIs) and the nonpeptidic viral protease inhibitors (PI), and their introduction in the management of patients with AIDS, either alone or in combination, have dramatically improved the clinical course of the disease and prolonged life expectancy in patients with AIDS. "

Related Drugs and Biologics

1.	Reverse Transcriptase Inhibitors
2.	Nucleotides
3.	Nucleosides
4.	Antiviral Agents (Antivirals)
5.	N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamide
6.	telaprevir
7.	Doxorubicin (Adriamycin)
8.	Ribavirin (Virazole)
9.	Interferons
10.	Indinavir (Crixivan)

Related Therapies and Procedures

1.	Highly Active Antiretroviral Therapy (HAART)
2.	Therapeutics